📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Biopharmaceutic Study Reports (OBX-319)

Document ID: CLINPHARM-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E

Biopharmaceutic Study Reports — OBX-319

Biopharmaceutic characterisation of OBX-319 (subcutaneous): absolute/relative bioavailability, dose proportionality, and the comparability of the clinical and to-be-marketed presentations. Subcutaneous absorption with typical IgG bioavailability; target-mediated drug disposition (TMDD) producing non-linear PK at low concentrations; distribution largely confined to plasma and interstitial fluid; elimination by proteolytic catabolism and (in the target-mediated component) receptor-mediated clearance. Classical small-molecule ADME (mass balance, CYP/transporter) is not applicable to an intact IgG. ICH M4E §5.3.1.

Product and rationale for the biopharmaceutic dataset

OBX-319 is a humanised IgG1 anti-CD19 × anti-CD20 B-cell-depleting bispecific monoclonal antibody, expressed in Chinese hamster ovary (CHO) cell culture and purified by a Protein A capture step followed by orthogonal polishing chromatography, formulated as a sterile aqueous liquid for subcutaneous administration. Because the active substance is an intact ~150 kDa glycoprotein rather than a small molecule, the biopharmaceutic programme is scoped to the questions that are meaningful for a parenteral biologic: the extent and rate of absorption from the subcutaneous depot, the dose–exposure relationship, and the comparability of systemic exposure across the clinical and to-be-marketed presentations. Biopharmaceutics Classification System (BCS) constructs of solubility, dissolution, and permeability, in vitro–in vivo correlation (IVIVC), radiolabelled mass-balance/ADME studies, and food-effect studies are not applicable to a subcutaneously administered antibody and were not conducted. Product quality and comparability are governed by ICH Q6B, Q5C, and Q5A(R2); nonclinical characterisation follows ICH S6(R1); the marketing application is a Biologics License Application under 21 CFR Part 601. Consistent with regulatory expectations for a monoclonal antibody, no genotoxicity, carcinogenicity, hERG, or thorough-QT assessments were included, as none is warranted for this modality.

Presentations and formulation bridging

Two presentations are relevant to Module 5.3.1: the drug product used to supply the pivotal Phase 3 study (OBX319-301) and the intended commercial (to-be-marketed) presentation. Both are the same liquid formulation of OBX-319 delivered by subcutaneous injection, with the injected volume kept within the range conventional for subcutaneous biologics (generally ≤ 2 mL per injection site). The comparability strategy for any change in container-closure or presentation between the clinical and commercial supply combines analytical/physicochemical comparability under ICH Q5E-type principles and the release and characterisation specifications of ICH Q6B with pharmacokinetic bridging, rather than a dissolution-based approach. Where the clinical and commercial products share the same cell line, manufacturing process, and formulation, analytical comparability serves as the primary evidence and is supplemented by the clinical exposure data described below.

Absorption and bioavailability

Following subcutaneous injection, OBX-319 reaches the systemic circulation predominantly through convective uptake into the lymphatics, with a smaller contribution from direct capillary absorption, giving the slow absorption profile characteristic of IgG1 antibodies (time to maximum concentration typically on the order of several days). Systemic bioavailability is in the range typical for subcutaneously administered IgG1 monoclonal antibodies (commonly ~50–80%), reflecting pre-systemic catabolism within the subcutaneous tissue and draining lymphatics; neonatal Fc receptor (FcRn)-mediated recycling protects the antibody from catabolism and contributes to its long systemic half-life. Because OBX-319 is developed as a subcutaneous-only product, an absolute bioavailability determination requiring an intravenous reference arm was not performed; absorption and bioavailability parameters were instead informed by the population pharmacokinetic disposition model, drawing on nonclinical (cynomolgus monkey) pharmacokinetic priors where appropriate. The cynomolgus monkey is the sole pharmacologically relevant species because the human CD19 and CD20 epitopes engaged by OBX-319 are not cross-reactive in rodents; nonclinical pharmacokinetics therefore rest on the cynomolgus data set.

Dose proportionality and non-linear (TMDD) exposure

Systemic exposure was characterised across the clinical dose levels (OBX-319 High, OBX-319 Low, Placebo). Target-mediated drug disposition dominates the low-concentration range: binding to CD19 and CD20 on circulating and tissue B cells provides a saturable, receptor-mediated clearance pathway superimposed on the linear catabolic pathway. As a consequence, exposure is expected to increase in a greater-than-dose-proportional manner across the studied dose range as the target-mediated component saturates, and clearance decreases with increasing dose and with depletion of the B-cell target pool over time. These features were captured in the population pharmacokinetic model rather than by non-compartmental dose-proportionality testing alone, and are consistent with the observed near-complete peripheral CD19+ B-cell depletion on the active arms.

Comparative bioavailability of clinical and to-be-marketed presentations

Comparability of the clinical and commercial presentations was addressed to support that the marketed product delivers equivalent systemic exposure to the material on which efficacy and safety were established. The assessment relies on standard pharmacokinetic comparison of peak (Cmax) and total (AUC) exposure against pre-specified acceptance bounds, interpreted together with the analytical comparability package. Potential differences in immunogenicity between presentations were considered as part of this comparison, since anti-drug antibodies can alter exposure.

Bioanalytical support and immunogenicity considerations

Serum OBX-319 concentrations were measured with a validated ligand-binding assay, and anti-drug antibodies were characterised with a tiered, validated assay strategy, each conducted in accordance with ICH M10 (see BIOANALYTICAL-001 and IMMUNO-001). Under target-mediated disposition the distinction between free and total analyte is material to interpretation, and the assay format was selected and reported accordingly. Immunogenicity is a relevant covariate for biopharmaceutic interpretation: treatment-emergent anti-drug antibodies can increase clearance and reduce exposure, and their impact on pharmacokinetics, efficacy, and safety is summarised in Module 2.7.

Distribution and elimination

Distribution of OBX-319 is largely confined to the plasma and interstitial fluid, with a volume of distribution approximating the plasma/extracellular space as expected for an intact IgG1. Elimination proceeds by proteolytic catabolism to peptides and amino acids—broadly distributed and not dependent on hepatic cytochrome P450 metabolism or renal excretion of intact antibody—together with the receptor-mediated (target-mediated) clearance component. Accordingly, classical small-molecule drug–drug interaction pathways (CYP enzymes and membrane transporters) are not applicable; therapeutic-protein interaction considerations are limited to indirect effects and are addressed within the clinical pharmacology summary. ICH M4E §5.3.1; ICH M10; ICH Q6B.